0001209191-21-051275.txt : 20210812
0001209191-21-051275.hdr.sgml : 20210812
20210812200045
ACCESSION NUMBER: 0001209191-21-051275
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210810
FILED AS OF DATE: 20210812
DATE AS OF CHANGE: 20210812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cohen Chad M
CENTRAL INDEX KEY: 0001524314
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 211169299
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVENUE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-10
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001524314
Cohen Chad M
C/O ADAPTIVE BIOTECHNOLOGIES CORP.
SUITE 200
SEATTLE
WA
98102
0
1
0
0
Chief Financial Officer
Common Stock
2021-08-10
4
M
0
5000
6.55
A
26604
D
Common Stock
2021-08-10
4
S
0
5000
35.00
D
21604
D
Common Stock
2021-08-11
4
M
0
10000
6.55
A
31604
D
Common Stock
2021-08-11
4
S
0
8738
33.48
D
22866
D
Common Stock
2021-08-11
4
S
0
1262
34.47
D
21604
D
Stock Option (Right to Buy)
6.55
2021-08-10
4
M
0
5000
0.00
D
2028-02-07
Common Stock
5000
85000
D
Stock Option (Right to Buy)
6.55
2021-08-11
4
M
0
10000
0.00
D
2028-02-07
Common Stock
10000
75000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.79 to 35.345, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.14 to 34.11, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.26 to 34.58, inclusive.
The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Chad Cohen by Eric Billings, Attorney-in-Fact
2021-08-12